Insider Selling: Encompass Health Corp (EHC) Insider Sells 28,955 Shares of Stock

Encompass Health Corp (AMEX:EHC) insider Cheryl B. Levy sold 28,955 shares of the stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $78.00, for a total transaction of $2,258,490.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of EHC stock traded down $0.42 on Friday, hitting $57.67. The company’s stock had a trading volume of 620,391 shares, compared to its average volume of 618,344. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.34 and a current ratio of 1.34. Encompass Health Corp has a fifty-two week low of $40.86 and a fifty-two week high of $59.29.

Encompass Health (AMEX:EHC) last released its quarterly earnings results on Wednesday, July 25th. The company reported $0.99 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.83 by $0.16. Encompass Health had a net margin of 8.67% and a return on equity of 23.56%. The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.03 billion. Encompass Health’s revenue for the quarter was up 10.5% compared to the same quarter last year. analysts anticipate that Encompass Health Corp will post 2.72 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 15th. Investors of record on Monday, October 1st will be paid a $0.27 dividend. The ex-dividend date is Friday, September 28th. This is an increase from Encompass Health’s previous quarterly dividend of $0.25. This represents a $1.08 annualized dividend and a dividend yield of 1.87%.

Several equities analysts have recently weighed in on EHC shares. Piper Jaffray Companies raised shares of Encompass Health from a “neutral” rating to an “overweight” rating in a research report on Thursday, July 26th. Zacks Investment Research raised shares of Encompass Health from a “hold” rating to a “buy” rating and set a $84.00 price objective on the stock in a research report on Friday, July 27th. Mizuho reissued a “buy” rating and issued a $82.00 price objective on shares of Encompass Health in a research report on Thursday, July 26th. Credit Suisse Group increased their price objective on shares of Encompass Health from $66.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday, July 26th. Finally, SunTrust Banks reissued a “buy” rating and issued a $82.00 price objective on shares of Encompass Health in a research report on Friday, July 20th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $71.10.

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in Encompass Health during the first quarter worth about $622,184,000. JPMorgan Chase & Co. acquired a new stake in Encompass Health during the first quarter worth about $221,881,000. Lord Abbett & CO. LLC acquired a new stake in Encompass Health during the first quarter worth about $116,238,000. Victory Capital Management Inc. acquired a new stake in Encompass Health during the first quarter worth about $101,978,000. Finally, Northern Trust Corp acquired a new stake in Encompass Health during the first quarter worth about $88,764,000. Institutional investors and hedge funds own 93.18% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation, formerly HealthSouth Corporation, is a provider of post-acute healthcare services, offering both facility-based and home-based post-acute services in 35 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies.

Read More: Return on Investment (ROI) Defined, Explained

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply